

FAX COVER SHEET**FAX RECEIVED**

OCT 15 2001

GROUP 1600

No. of pages incl. this: 10

Telefax no.: (703) 308-4556

To: U.S. Patent and Trademark Office
Examiner Delia Ramirez

From: Elias J. Lambiris

Date: October 15, 2001

Message:

As per your request, attached is a copy of the information
disclosure statement mailed on March 6, 2000.

The information contained in this facsimile message is legally privileged and confidential information intended solely for the use of the persons or entities named below. If you are not such persons or entities, you are hereby notified that any distribution, dissemination or reproduction of this facsimile message is strictly prohibited. If you have received this message in error, please immediately call us collect at the above number.

**Novozymes
North America, Inc.**
Patents-US

405 Lexington Av.,
Suite 6400
New York, NY 10174-6401

Telephone:
(212)-878-9652
Telefax:
(212)-867-0298

email:
elam@novozymes.com
internet:
www.novozymes.com

Attorney Docket No.: 5808.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Martin Lehmann

Application No.: 09/488,265

Group Art Unit: TBA

Filed: January 20, 2000

Examiner: TBA

For: Improved Phytases

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)Assistant Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Transmittal of Information Disclosure Statement
2. Information Disclosure Statement
3. Form PTO-1449
4. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner of Patents and Trademarks
Washington, DC 20231

on March 6, 2000.

Miriam Kelly

(name of person mailing paper)


(signature of person mailing paper)

Attorney Docket No.: 5808.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Martin Lehmann

Application No.: 09/488,265

Group Art Unit: TBA

Filed: January 20, 2000

Examiner: TBA

For: Improved Phytases


**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF FILING OR
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))**Assistant Commissioner for Patents
Washington, DC 20231

Sir:

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. § 1.97(b). Therefore, no fee is due.

Respectfully submitted,

Date: March 6, 2000



Carol E. Rozek, Reg. No. 36,993
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

Attorney Docket No.: 5808.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Martin Lehmann

Application No.: 09/488,265

Group Art Unit: TBA

Filed: January 20, 2000

Examiner: TBA

For: Improved Phytases

INFORMATION DISCLOSURE STATEMENTAssistant Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. EP 0 897 985
2. EP 0 897 010
3. EP 0 684 313
4. EP 0 747 483
5. EP 0 183 070
6. EP 0 263 311


7. EP 0 248 227
8. EP 0 183 071
9. EP 0 207 459
10. EP 0 405 370
11. EP 0 299 108
12. EP 0 420 358
13. WO 98/28409
14. WO 97/35017
15. Goeddel (ED.), et al., *Methods in Enzymology*, Vol. 185, pp. 199-228
16. Wu (ED.), *Methods in Enzymology*, Vol. 155, pp. 416-433
17. Berka et al., *Applied and Environmental Microbiology*, Vol. 64, No. 11, pp. 4423-4427 (Nov. 1998)
18. Pasamontes et al., *Biochimica et Biophysica Acta*, Vol. 1353, pp. 217-223 (1997)
19. Matthews, *Biochemistry*, Vol. 26, No. 22, pp. 6885-6888 (Nov. 3, 1987)
20. Gottesman et al., *Journal of Bacteriology*, Vol. 148, No. 1, pp. 265-273 (Oct. 1981)
21. Punt et al., *GENE*, Vol. 69, pp. 49-57 (1988)
22. Hartingsveld et al., *GENE*, Vol. 127, pp. 87-94 (1993)
23. Schindler et al., *GENE*, Vol. 130, pp. 271-275 (1993)
24. Mac Rae et al., *GENE*, Vol. 132, pp. 193-198 (1993)
25. Boddy et al., *Current Genetics*, Vol. 24, pp. 60-66 (1993)
26. MacRae et al., *GENE*, Vol. 71, pp. 339-348 (1988)
27. Piddington et al., *GENE*, Vol. 133, pp. 55-62 (1993)
28. Graaff et al., *Current Genetics*, Vol. 22, pp. 21-27 (1992)
29. Matthews, *Curr. Opinion in Structural Biology*, Vol. 1, pp. 17-21 (1991)
30. Fersht et al., *Curr. Opinion in Structural Bio.*, Vol. 3, pp. 75-83 (1993)
31. Punt et al., *Journal of Biotechnology*, Vol. 17, pp. 19-34 (1991)
32. Koutz et al., *Yeast*, Vol. 5, pp. 167-177 (1989)
33. Hitzeman et al., *Nature*, Vol. 293, No. 29, pp. 717-722 (1981)
34. Yansura et al., *Proc. Natl. Acad. Sci. USA*, Vol. 81, pp. 439-443 (Jan. 1984)
35. Stanssens et al., *Nucleic Acids Research*, Vol. 17, No. 12, pp. 4441-4455 (1989)
36. Ledebroer et al., *Nucleic Acids Research*, Vol. 13, No. 9, pp. 3063-3083 (1985)
37. Devereux et al., *Nucleic Acids Res.* Vol. 12, No. 1, pp. 387-395 (1984)
38. Vogel et al., *Molecular and Cellular Biol.*, Vol. 9, No. 5 pp. 2050-2057 (May 1989)
39. Janacek, *Process Biochem.*, Vol. 28, pp. 435-445 (1993)
40. Sreekrishna et al., *J. Basic Microbiol.*, Vol. 28, No. 4, pp. 265-278 (1988)
41. Smith, *Ann. Rev. Genet.*, Vol. 19, pp. 423-462 (1985)
42. Gellissen et al., *Bio/Technology*, Vol. 9, pp. 291-295 (March 1991)
43. Harkki et al., *Bio/Technology*, Vol. 7, (June 1989)
44. Christensen et al., *Bio/Technology*, Vol. 6, pp. 1419-1422 (1988)
45. Pen et al., *Bio/Technology*, Vol. 11, pp. 811-814 (July 1993)
46. Upshall et al., *Bio/Technology*, Vol. 5, pp. 1301-1304 (Dec. 1987)
47. Cullen et al., *Bio/Technology*, Vol. 5, pp. 369-376 (April 1987)

48. Gwynne et al., Bio/Technology, Vol. 5, pp. 713-719 (July 1987)
49. Goldstein et al., Bio/Technology, Vol. 5, pp. 72-79 (Jan. 1987)
50. Pasamontes et al., Applied and Env. Microbiol., Vol. 63, No. 5, pp. 1696-1700 (May 1997)
51. Alber, Annu. Rev. Biochem., Vol. 58, pp. 765-798 (1989)
52. Mitchell et al., Microbiology, Vol. 143, pp. 245-252 (1997)
53. Villarejo et al., Journal of Bacteriology, Vol. 120, No. 1, pp. 466-474 (Oct. 1974)
54. Needleman et al., J. Mol. Biol., Vol. 48, pp. 443-453, (1970)
55. Stüber et al., Immunological Methods, Vol. IV, pp. 121-153 (1990)
56. Rudolph et al., Proc. Natl. Acad. Sci. USA, Vol. 84, pp. 1340-1344 (March 1987)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

Respectfully submitted,

Date: March 6, 2000


Carol E. Rozek, Reg. No. 36,993
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123